David McDermott
大卫·麦克德莫特
MD
Director, Biologic Therapy and Cutaneous Oncology Program生物治疗与皮肤肿瘤项目主任
👥Biography 个人简介
David McDermott is a pioneering renal cell carcinoma immunotherapy specialist with landmark contributions to high-dose IL-2 therapy and combined checkpoint inhibition. His CheckMate-214 work establishing nivolumab+ipilimumab as first-line RCC therapy transformed clinical practice.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Nivolumab + Ipilimumab Combination in RCC
Co-led CheckMate-214 trial demonstrating nivolumab plus ipilimumab superiority over sunitinib for intermediate/poor-risk advanced RCC, establishing a new immunotherapy standard of care.
High-Dose IL-2 and Immunotherapy Biomarkers
Pioneered research into high-dose IL-2 therapy patient selection and biomarkers predicting durable responses in metastatic RCC and melanoma patients.
Representative Works 代表性著作
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
New England Journal of Medicine (2018)
CheckMate-214 demonstrating nivolumab+ipilimumab combination improved OS versus sunitinib in intermediate/poor-risk advanced RCC, leading to FDA approval.
Survival, Durable Response, and Long-Term Safety in Patients with Previously Treated Advanced Renal Cell Carcinoma
Journal of Clinical Oncology (2015)
Long-term follow-up data establishing nivolumab monotherapy as effective second-line therapy for advanced renal cell carcinoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Dean Bajorin
Memorial Sloan Kettering Cancer Center
Jonathan Rosenberg
Memorial Sloan Kettering Cancer Center
Thomas Powles
Barts Cancer Institute, Queen Mary University of London
Andrea Necchi
Vita-Salute San Raffaele University
关注 大卫·麦克德莫特 的研究动态
Follow David McDermott's research updates
留下邮箱，当我们发布与 David McDermott（Beth Israel Deaconess Medical Center, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment